PDCD1 and neoplasm: Secondly, tumor cells present resistance to immune checkpoint inhibitors 28 with natural and acquired resistance to PD-1 and PD-L1 inhibitors in various tumors such as melanoma, NSCLC, kidney cancer, and so on 29.